- Report
- November 2024
- 90 Pages
Global
From €5273EUR$5,950USD£4,541GBP
- Report
- July 2025
- 100 Pages
Global
From €4342EUR$4,900USD£3,739GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- June 2025
- 150 Pages
Global
From €3412EUR$3,850USD£2,938GBP
- Report
- July 2025
- 178 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- July 2025
- 212 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- May 2024
- 138 Pages
Global
From €5759EUR$6,499USD£4,960GBP
- Report
- May 2024
- 138 Pages
Global
From €5759EUR$6,499USD£4,960GBP
- Report
- November 2023
- 432 Pages
Global
From €8419EUR$9,500USD£7,250GBP
- Report
- November 2023
- 230 Pages
Global
From €6646EUR$7,500USD£5,724GBP
- Report
- January 2022
- 160 Pages
Global
From €8419EUR$9,500USD£7,250GBP
- Report
- September 2024
- 82 Pages
Japan
From €2636EUR$2,975USD£2,270GBP
€3102EUR$3,500USD£2,671GBP
- Report
- February 2024
- 110 Pages
Global
From €4209EUR$4,750USD£3,625GBP
- Report
- January 2021
- 124 Pages
Global
From €3190EUR$3,600USD£2,747GBP
- Report
- August 2019
- 212 Pages
Global
From €13288EUR$14,995USD£11,444GBP
- Report
- January 2024
- 129 Pages
United States
€3367EUR$3,800USD£2,900GBP

Apalutamide is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of androgens, hormones that can cause prostate cancer cells to grow. Apalutamide is used in combination with other treatments, such as hormone therapy, to slow the growth of prostate cancer. It is approved by the US Food and Drug Administration (FDA) for the treatment of non-metastatic castration-resistant prostate cancer.
Apalutamide is a relatively new drug, and is part of a growing class of prostate cancer treatments. It is one of several drugs that have been developed to target androgen receptors, which are proteins that can cause prostate cancer cells to grow. Other drugs in this class include enzalutamide and abiraterone.
Apalutamide is available in the US and Europe, and is marketed by several pharmaceutical companies. These include Janssen Pharmaceuticals, Astellas Pharma, and Bayer. Show Less Read more